Impact of Blockade of Histamine H2 Receptors on Chronic Heart Failure Revealed by Retrospective and Prospective Randomized Studies
Jiyoong Kim, MD,
Akiko Ogai, MS,
Satoshi Nakatani, MD, PhD,
Kazuhiko Hashimura, MD,
Hideaki Kanzaki, MD,
Kazuo Komamura, MD, PhD,
Masanori Asakura, MD, PhD,
Hiroshi Asanuma, MD, PhD,
Soichiro Kitamura, MD, PhD,
Hitonobu Tomoike, MD, PhD and
Masafumi Kitakaze, MD, PhD*
Cardiovascular Division, National Cardiovascular Center, Suita, Japan
View larger version (18K):
[in a new window]
|
Figure 1 Changes in the plasma B-type natriuretic peptide (BNP) levels (A) and New York Heart Association (NYHA) functional classification (B) before and after the treatment with (the famotidine group) or without famotidine (the control group). The plasma BNP levels are statistically analyzed after the log transformation. The p values are obtained using 2-way repeated-measures analysis of variance (A) or Wilcoxon signed rank test (B).
|
|
View larger version (9K):
[in a new window]
|
Figure 2 Changes in left ventricular (LV) end-diastolic volume (LVDd) (A) or end-systolic volume (LVDs) (B), LV fractional shortening (FS) (C), left atrial diameter (LAD) (D), and the pressure differences across the tricuspid valve (TR dPmax) (E) before and after 24 weeks of treatment in the control and famotidine groups. The p values are tested using 2-way repeated-measures analysis of variance.
|
|
|
